We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » As Drug Candidate Numbers Soar, Developing Treatments for Neurodegenerative Diseases Remains Challenging
As Drug Candidate Numbers Soar, Developing Treatments for Neurodegenerative Diseases Remains Challenging
The neurodegenerative disease drug development pipeline is full, but getting investigative drugs over the FDA finish line is both a biological and regulatory challenge.